SCHEMBL79678

SCHEMBL79678

CC(C)(C)c1ccc(OC=O)cc1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA1 P00915 1/20 0.48
CA2 P00918 1/20 0.48
CA9 Q16790 1/20 0.48
MAPT P10636 4/20 0.47
ALDH1A1 P00352 3/20 0.47
RAB9A P51151 3/20 0.47
MAPK1 P28482 2/20 0.47
NPC1 O15118 2/20 0.47
HPGD P15428 1/20 0.47
SMN1; SMN2 Q16637 2/20 0.46
TDP1 Q9NUW8 2/20 0.43
L3MBTL1 Q9Y468 1/20 0.43
TSHR P16473 3/20 0.42
MAOB P27338 1/20 0.42
AOC3 Q16853 1/20 0.42
LMNA P02545 2/20 0.42
ALOX15 P16050 1/20 0.42
APEX1 P27695 1/20 0.42
RECQL P46063 1/20 0.42
HSD17B10 Q99714 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28774589 0.98 CA1 (0.47) CA1CA2CA9MAPTALDH1A1
SCHEMBL7590568 0.86 HPGD (0.41) CA1CA2CA9MAPTALDH1A1
SCHEMBL11780605 0.86 SMN1; SMN2 (0.40) CA1CA2CA9MAPTALDH1A1
SCHEMBL1936878 0.83 CA1 (0.46) CA1CA2CA9MAPTALDH1A1
SCHEMBL6454577 0.80 ALDH1A1 (0.38) CA1CA2CA9ALDH1A1SMN1; SMN2
SCHEMBL12329883 0.79 ALDH1A1 (0.45) CA1CA2CA9MAPTALDH1A1
SCHEMBL12325325 0.79 TSHR (0.41) CA1CA2CA9MAPTALDH1A1
SCHEMBL18383534 0.79 HSD11B1 (0.38) CA1CA2CA9MAPTALDH1A1
SCHEMBL13447587 0.79 SMN1; SMN2 (0.49) ALDH1A1RAB9ANPC1SMN1; SMN2TDP1
SCHEMBL8140565 0.79 MAPT (0.48) CA1CA2CA9MAPTALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1478 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-5234930-A Treating psychological, cardiovascular, urogenital and respiratory disorders; diabetes, asthmas, sudden infant death syndrome FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1993-08-10 US claimed
EP-0354297-B1 THIADIAZINES, PROCESS FOR PRODUCTION THEREOF, AND INSECTICIDAL AND ACARICIDAL AGENTS COMPRISING THE THIADIAZINES MITSUI TOATSU CHEMICALS, Inc. (JP) 1992-08-05 EP claimed
CN-118202006-A Resin composition, cured product, optical member, ultraviolet absorber, compound, method for producing compound, and polymer 富士胶片株式会社 2024-06-14 CN disclosed
CN-118176445-A Light absorbing filter, light filter, method for manufacturing light absorbing filter, organic electroluminescent display device, inorganic electroluminescent display device, and liquid crystal display device 富士胶片株式会社 2024-06-11 CN disclosed
US-11993697-B2 Flexible tube for endoscope, endoscopic medical device, and resin composition for covering flexible tube substrate for endoscope FUJIFILM CORPORATION (JP) 2024-05-28 US disclosed
US-11958959-B2 Lens for spectacles and spectacles FUJIFILM CORPORATION (JP) 2024-04-16 US disclosed
WO-2024062843-A1 COLORED COMPOSITION, COLORED PRODUCT, AND COMPOUND 富士フイルム株式会社 2024-03-28 WO disclosed
US-20240084106-A1 KNEADED MATERIAL, METHOD OF PRODUCING KNEADED MATERIAL, MOLDED BODY, AND OPTICAL MEMBER FUJIFILM CORPORATION (JP) 2024-03-14 US disclosed
EP-3646770-B1 ENDOSCOPE FLEXIBLE TUBE, ENDOSCOPE-TYPE MEDICAL DEVICE, RESIN COMPOSITION FOR COATING ENDOSCOPE FLEXIBLE-TUBE SUBSTRATE, AND RESIN COMPOSITION SET FOR COATING ENDOSCOPE FLEXIBLE-TUBE SUBSTRATE FUJIFILM CORP (JP) 2024-03-13 EP disclosed
US-20240067846-A1 PHOTOPOLYMERIZABLE COMPOSITION, CURED SUBSTANCE, AND OPTICAL MEMBER FUJIFILM CORPORATION (JP) 2024-02-29 US disclosed
US-20240051916-A1 METHOD FOR PRODUCING N-(HETERO)ARYL (METH)ACRYLAMIDE COMPOUND FUJIFILM CORPORATION (JP) 2024-02-15 US disclosed
EP-0264106-A2 5-Substituted amino-4-hydroxy-pentanoic acid derivatives and their use Banyu Pharmaceutical Co., Ltd. (JP) 1988-04-20 EP disclosed
US-4732998-A Bisphosphonic acids and esters LEO PHARMACEUTICAL PRODUCTS, LTD. (DK) 1988-03-22 US disclosed
US-4652648-A STABILIZERS FOR HEAT, OXIDATION AND LIGHT CIBA-GEIGY CORPORATION (US) 1987-03-24 US disclosed
EP-0191044-A1 DERIVATIVES OF METHYLENE-BISPHOSPHONIC ACID, PROCESS FOR THEIR PREPARATION AND A PHARMACEUTICAL COMPOSITION. LEO PHARM PROD LTD (DK) 1986-08-20 EP disclosed
US-4579682-A HEAT, OXYGEN, AND LIGHT PROTECTION FOR POLYMERS CIBA-GEIGY CORPORATION (US) 1986-04-01 US disclosed
WO-1986000902-A1 DERIVATIVES OF METHYLENE-BISPHOSPHONIC ACID, PROCESS FOR THEIR PREPARATION AND A PHARMACEUTICAL COMPOSITION LEO PHARMACEUTICAL PRODUCTS LTD. A/S (DK) 1986-02-13 WO disclosed
US-4434109-A STABILIZERS AGAINST HEAT, OXYGEN AND LIGHT CIBA-GEIGY CORPORATION (US) 1984-02-28 US disclosed
US-4259350-A PROTECTING DEGRADABLE ORGANIC MATERIAL FROM FUNGAL OR INSECT ATTACK SANKYO COMPANY LIMITED (JP) 1981-03-31 US disclosed
US-4255301-A HEAT RESISTANCE, PHOTOSTABILITY ARGUS CHEMICAL CORPORATION (US) 1981-03-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240051916-A1 METHOD FOR PRODUCING N-(HETERO)ARYL (METH)ACRYLAMIDE COMPOUND NAT1, AHR, PAM CA1 4202/4885CA2 3603/4885CA9 3288/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.